×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CTXR – citius pharmaceuticals, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CTXR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
04:05 pm
ctxr
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
High
Report
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
11/15
01:30 pm
ctxr
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
High
Report
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
11/12
08:33 am
ctxr
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
11/11
08:45 am
ctxr
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Low
Report
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
9/5
04:30 pm
ctxr
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
9/5
08:30 am
ctxr
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
Medium
Report
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
Date
Time
Symbol
Company Name
Action
%Chg
8/12/2024
05:28 pm
ctxr
citius pharmaceuticals, inc.
MISS
Report
-10.9%
citius pharmaceuticals, inc.
8/12/2024
05:28 pm
ctxr
citius pharmaceuticals, inc.
MISS
Report
-10.9%
citius pharmaceuticals, inc.
8/12/2024
05:28 pm
ctxr
citius pharmaceuticals, inc.
MISS
Report
-10.2%
citius pharmaceuticals, inc.
5/14/2024
04:05 pm
ctxr
citius pharmaceuticals, inc.
BEAT
Report
-9.1%
citius pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
04:15 pm
ctxr
Form 8-K Citius Pharmaceuticals, For: Nov 15
High
Report
Form 8-K Citius Pharmaceuticals, For: Nov 15
11/18
08:30 am
ctxr
Form 424B5 Citius Pharmaceuticals,
Medium
Report
Form 424B5 Citius Pharmaceuticals,
11/13
04:30 pm
ctxr
Form 8-K Citius Pharmaceuticals, For: Nov 06
High
Report
Form 8-K Citius Pharmaceuticals, For: Nov 06
11/12
05:01 pm
ctxr
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Mazur Leonard L
High
Report
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Mazur Leonard L
11/12
05:01 pm
ctxr
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Smith Robert Joseph
High
Report
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Smith Robert Joseph
11/12
05:01 pm
ctxr
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Webb Carol
High
Report
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Webb Carol
11/12
05:01 pm
ctxr
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: HOLUBIAK MYRON Z
High
Report
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: HOLUBIAK MYRON Z
11/12
05:01 pm
ctxr
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Dutia Suren G
High
Report
Form 4 Citius Pharmaceuticals, For: Nov 07 Filed by: Dutia Suren G
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/10
Form 4 Citius Pharmaceuticals, For: Oct 08 Filed by: Dutia Suren G
26.8%
4/1 Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 22.4%
4/28 Form 8-K Citius Pharmaceuticals, For: Apr 27 19.2%
10/15 Citius Pharmaceuticals to Present at the MicroCap Rodeo 14.1%
1/22 Form 8-K Citius Pharmaceuticals, For: Jan 22 13.0%
12/20 Form DEFA14A Citius Pharmaceuticals, 9.4%
2/13 Form 10-Q Citius Pharmaceuticals, For: Dec 31 8.9%
9/20 Citius Pharma -9.5% after filing to offer units [Seeking Alpha] 8.4%
5/15 Form 10-Q Citius Pharmaceuticals, For: Mar 31 7.6%
4/24 Form 424B3 Citius Pharmaceuticals, 7.5%
4/1 Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 22.4%
4/28 Form 8-K Citius Pharmaceuticals, For: Apr 27 19.2%
10/15 Citius Pharmaceuticals to Present at the MicroCap Rodeo 14.1%
1/22 Form 8-K Citius Pharmaceuticals, For: Jan 22 13.0%
12/20 Form DEFA14A Citius Pharmaceuticals, 9.4%
2/13 Form 10-Q Citius Pharmaceuticals, For: Dec 31 8.9%
9/20 Citius Pharma -9.5% after filing to offer units [Seeking Alpha] 8.4%
5/15 Form 10-Q Citius Pharmaceuticals, For: Mar 31 7.6%
4/24 Form 424B3 Citius Pharmaceuticals, 7.5%
TOP News Decliners
2/14
Form 8-K Citius Pharmaceuticals, For: Feb 14
-16.9%
9/23 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -14.4%
4/29 Form 8-K Citius Pharmaceuticals, For: Apr 29 -12.4%
1/25 Citius Pharmaceuticals Inc (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock. -10.3%
9/4 Form 8-K Citius Pharmaceuticals, For: Sep 04 -9.6%
3/4 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
9/9 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.2%
4/3 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.0%
2/3 Form 8-K Citius Pharmaceuticals, For: Jan 31 -7.6%
2/4 Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial -6.7%
9/23 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -14.4%
4/29 Form 8-K Citius Pharmaceuticals, For: Apr 29 -12.4%
1/25 Citius Pharmaceuticals Inc (NASDAQ: CTXR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock. -10.3%
9/4 Form 8-K Citius Pharmaceuticals, For: Sep 04 -9.6%
3/4 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -8.3%
9/9 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.2%
4/3 Citius Pharmaceuticals Inc (NASDAQ: CTXR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.0%
2/3 Form 8-K Citius Pharmaceuticals, For: Jan 31 -7.6%
2/4 Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial -6.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: